Telix Pharmaceuticals (NASDAQ:TLX – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Wednesday, Benzinga reports. They currently have a $22.00 target price on the stock. Wedbush‘s price target would suggest a potential upside of 140.31% from the stock’s previous close.
Several other analysts have also issued reports on the stock. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Citigroup restated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Finally, Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $20.50.
Check Out Our Latest Stock Analysis on TLX
Telix Pharmaceuticals Stock Down 4.0%
Institutional Investors Weigh In On Telix Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals during the second quarter valued at $1,731,000. Private Advisor Group LLC increased its position in Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares during the last quarter. XY Capital Ltd increased its position in Telix Pharmaceuticals by 468.0% during the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after acquiring an additional 58,739 shares during the last quarter. WoodTrust Financial Corp bought a new position in shares of Telix Pharmaceuticals in the third quarter worth about $186,000. Finally, Bank of America Corp DE grew its holdings in shares of Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after purchasing an additional 8,423 shares during the last quarter.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.
The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
